ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Myasthenia Gravis Drugs Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-13H14066
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Myasthenia Gravis Drugs Market Insights Forecast to 2029
BUY CHAPTERS

Global Myasthenia Gravis Drugs Market Research Report 2025

Code: QYRE-Auto-13H14066
Report
January 2025
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Flamel Technologies
F.Hoffmann-La Roche
Grifols S A
Bausch Health
Alexion Pharmaceuticals
Catalyst Pharmaceuticals
CSL Limited
CuraVac Inc
Cytokinetics Inc
Galencia
GlaxoSmithKline PLC
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
Novartis
Takeda
Pfizer Inc

Myasthenia Gravis Drugs Market Size

The global market for Myasthenia Gravis Drugs was valued at US$ 1548 million in the year 2024 and is projected to reach a revised size of US$ 2569 million by 2031, growing at a CAGR of 7.6% during the forecast period.

Myasthenia Gravis Drugs Market

Myasthenia Gravis Drugs Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Myasthenia Gravis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myasthenia Gravis Drugs.
The Myasthenia Gravis Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Myasthenia Gravis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myasthenia Gravis Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Myasthenia Gravis Drugs Market Report

Report Metric Details
Report Name Myasthenia Gravis Drugs Market
Accounted market size in year US$ 1548 million
Forecasted market size in 2031 US$ 2569 million
CAGR 7.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospitals
  • Clinics
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Takeda, Novartis, Bausch Health, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Myasthenia Gravis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Myasthenia Gravis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Myasthenia Gravis Drugs Market growing?

Ans: The Myasthenia Gravis Drugs Market witnessing a CAGR of 7.6% during the forecast period 2025-2031.

What is the Myasthenia Gravis Drugs Market size in 2031?

Ans: The Myasthenia Gravis Drugs Market size in 2031 will be US$ 2569 million.

Who are the main players in the Myasthenia Gravis Drugs Market report?

Ans: The main players in the Myasthenia Gravis Drugs Market are Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Takeda, Novartis, Bausch Health, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma

What are the Application segmentation covered in the Myasthenia Gravis Drugs Market report?

Ans: The Applications covered in the Myasthenia Gravis Drugs Market report are Hospitals, Clinics

What are the Type segmentation covered in the Myasthenia Gravis Drugs Market report?

Ans: The Types covered in the Myasthenia Gravis Drugs Market report are Anticholinesterases, Immunosuppressants, Intravenous Immune Globulins

Recommended Reports

Neuromuscular Diseases

Neurodegenerative Drugs

Autoimmune & Immune Disorders

1 Myasthenia Gravis Drugs Market Overview
1.1 Product Definition
1.2 Myasthenia Gravis Drugs by Type
1.2.1 Global Myasthenia Gravis Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Anticholinesterases
1.2.3 Immunosuppressants
1.2.4 Intravenous Immune Globulins
1.3 Myasthenia Gravis Drugs by Application
1.3.1 Global Myasthenia Gravis Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.4 Global Myasthenia Gravis Drugs Market Size Estimates and Forecasts
1.4.1 Global Myasthenia Gravis Drugs Revenue 2020-2031
1.4.2 Global Myasthenia Gravis Drugs Sales 2020-2031
1.4.3 Global Myasthenia Gravis Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Myasthenia Gravis Drugs Market Competition by Manufacturers
2.1 Global Myasthenia Gravis Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Myasthenia Gravis Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Myasthenia Gravis Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Myasthenia Gravis Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Myasthenia Gravis Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Myasthenia Gravis Drugs, Product Type & Application
2.7 Global Key Manufacturers of Myasthenia Gravis Drugs, Date of Enter into This Industry
2.8 Global Myasthenia Gravis Drugs Market Competitive Situation and Trends
2.8.1 Global Myasthenia Gravis Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Myasthenia Gravis Drugs Players Market Share by Revenue
2.8.3 Global Myasthenia Gravis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Myasthenia Gravis Drugs Market Scenario by Region
3.1 Global Myasthenia Gravis Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Myasthenia Gravis Drugs Sales by Region: 2020-2031
3.2.1 Global Myasthenia Gravis Drugs Sales by Region: 2020-2025
3.2.2 Global Myasthenia Gravis Drugs Sales by Region: 2026-2031
3.3 Global Myasthenia Gravis Drugs Revenue by Region: 2020-2031
3.3.1 Global Myasthenia Gravis Drugs Revenue by Region: 2020-2025
3.3.2 Global Myasthenia Gravis Drugs Revenue by Region: 2026-2031
3.4 North America Myasthenia Gravis Drugs Market Facts & Figures by Country
3.4.1 North America Myasthenia Gravis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Myasthenia Gravis Drugs Sales by Country (2020-2031)
3.4.3 North America Myasthenia Gravis Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Myasthenia Gravis Drugs Market Facts & Figures by Country
3.5.1 Europe Myasthenia Gravis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Myasthenia Gravis Drugs Sales by Country (2020-2031)
3.5.3 Europe Myasthenia Gravis Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Myasthenia Gravis Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Myasthenia Gravis Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Myasthenia Gravis Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Myasthenia Gravis Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Myasthenia Gravis Drugs Market Facts & Figures by Country
3.7.1 Latin America Myasthenia Gravis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Myasthenia Gravis Drugs Sales by Country (2020-2031)
3.7.3 Latin America Myasthenia Gravis Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Myasthenia Gravis Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Myasthenia Gravis Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Myasthenia Gravis Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Myasthenia Gravis Drugs Sales by Type (2020-2031)
4.1.1 Global Myasthenia Gravis Drugs Sales by Type (2020-2025)
4.1.2 Global Myasthenia Gravis Drugs Sales by Type (2026-2031)
4.1.3 Global Myasthenia Gravis Drugs Sales Market Share by Type (2020-2031)
4.2 Global Myasthenia Gravis Drugs Revenue by Type (2020-2031)
4.2.1 Global Myasthenia Gravis Drugs Revenue by Type (2020-2025)
4.2.2 Global Myasthenia Gravis Drugs Revenue by Type (2026-2031)
4.2.3 Global Myasthenia Gravis Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Myasthenia Gravis Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Myasthenia Gravis Drugs Sales by Application (2020-2031)
5.1.1 Global Myasthenia Gravis Drugs Sales by Application (2020-2025)
5.1.2 Global Myasthenia Gravis Drugs Sales by Application (2026-2031)
5.1.3 Global Myasthenia Gravis Drugs Sales Market Share by Application (2020-2031)
5.2 Global Myasthenia Gravis Drugs Revenue by Application (2020-2031)
5.2.1 Global Myasthenia Gravis Drugs Revenue by Application (2020-2025)
5.2.2 Global Myasthenia Gravis Drugs Revenue by Application (2026-2031)
5.2.3 Global Myasthenia Gravis Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Myasthenia Gravis Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Flamel Technologies
6.1.1 Flamel Technologies Company Information
6.1.2 Flamel Technologies Description and Business Overview
6.1.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Flamel Technologies Myasthenia Gravis Drugs Product Portfolio
6.1.5 Flamel Technologies Recent Developments/Updates
6.2 F. Hoffmann-La Roche
6.2.1 F. Hoffmann-La Roche Company Information
6.2.2 F. Hoffmann-La Roche Description and Business Overview
6.2.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Product Portfolio
6.2.5 F. Hoffmann-La Roche Recent Developments/Updates
6.3 Grifols
6.3.1 Grifols Company Information
6.3.2 Grifols Description and Business Overview
6.3.3 Grifols Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Grifols Myasthenia Gravis Drugs Product Portfolio
6.3.5 Grifols Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer Myasthenia Gravis Drugs Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Takeda
6.5.1 Takeda Company Information
6.5.2 Takeda Description and Business Overview
6.5.3 Takeda Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Takeda Myasthenia Gravis Drugs Product Portfolio
6.5.5 Takeda Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Company Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novartis Myasthenia Gravis Drugs Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Bausch Health
6.7.1 Bausch Health Company Information
6.7.2 Bausch Health Description and Business Overview
6.7.3 Bausch Health Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Bausch Health Myasthenia Gravis Drugs Product Portfolio
6.7.5 Bausch Health Recent Developments/Updates
6.8 Alexion Pharmaceuticals
6.8.1 Alexion Pharmaceuticals Company Information
6.8.2 Alexion Pharmaceuticals Description and Business Overview
6.8.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
6.8.5 Alexion Pharmaceuticals Recent Developments/Updates
6.9 Catalyst Pharmaceuticals
6.9.1 Catalyst Pharmaceuticals Company Information
6.9.2 Catalyst Pharmaceuticals Description and Business Overview
6.9.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
6.9.5 Catalyst Pharmaceuticals Recent Developments/Updates
6.10 CSL
6.10.1 CSL Company Information
6.10.2 CSL Description and Business Overview
6.10.3 CSL Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 CSL Myasthenia Gravis Drugs Product Portfolio
6.10.5 CSL Recent Developments/Updates
6.11 Curavac
6.11.1 Curavac Company Information
6.11.2 Curavac Description and Business Overview
6.11.3 Curavac Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Curavac Myasthenia Gravis Drugs Product Portfolio
6.11.5 Curavac Recent Developments/Updates
6.12 Cytokinetics
6.12.1 Cytokinetics Company Information
6.12.2 Cytokinetics Description and Business Overview
6.12.3 Cytokinetics Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Cytokinetics Myasthenia Gravis Drugs Product Portfolio
6.12.5 Cytokinetics Recent Developments/Updates
6.13 Galencia
6.13.1 Galencia Company Information
6.13.2 Galencia Description and Business Overview
6.13.3 Galencia Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Galencia Myasthenia Gravis Drugs Product Portfolio
6.13.5 Galencia Recent Developments/Updates
6.14 GlaxoSmithKline
6.14.1 GlaxoSmithKline Company Information
6.14.2 GlaxoSmithKline Description and Business Overview
6.14.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 GlaxoSmithKline Myasthenia Gravis Drugs Product Portfolio
6.14.5 GlaxoSmithKline Recent Developments/Updates
6.15 Lupin Pharmaceuticals
6.15.1 Lupin Pharmaceuticals Company Information
6.15.2 Lupin Pharmaceuticals Description and Business Overview
6.15.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
6.15.5 Lupin Pharmaceuticals Recent Developments/Updates
6.16 Mitsubishi Tanabe Pharma
6.16.1 Mitsubishi Tanabe Pharma Company Information
6.16.2 Mitsubishi Tanabe Pharma Description and Business Overview
6.16.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Portfolio
6.16.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Myasthenia Gravis Drugs Industry Chain Analysis
7.2 Myasthenia Gravis Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Myasthenia Gravis Drugs Production Mode & Process Analysis
7.4 Myasthenia Gravis Drugs Sales and Marketing
7.4.1 Myasthenia Gravis Drugs Sales Channels
7.4.2 Myasthenia Gravis Drugs Distributors
7.5 Myasthenia Gravis Drugs Customer Analysis
8 Myasthenia Gravis Drugs Market Dynamics
8.1 Myasthenia Gravis Drugs Industry Trends
8.2 Myasthenia Gravis Drugs Market Drivers
8.3 Myasthenia Gravis Drugs Market Challenges
8.4 Myasthenia Gravis Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Flamel Technologies
F.Hoffmann-La Roche
Grifols S A
Bausch Health
Alexion Pharmaceuticals
Catalyst Pharmaceuticals
CSL Limited
CuraVac Inc
Cytokinetics Inc
Galencia
GlaxoSmithKline PLC
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
Novartis
Takeda
Pfizer Inc
List of Tables
 Table 1. Global Myasthenia Gravis Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Myasthenia Gravis Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Myasthenia Gravis Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Myasthenia Gravis Drugs Sales (MT) of Key Manufacturers (2020-2025)
 Table 5. Global Myasthenia Gravis Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Myasthenia Gravis Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Myasthenia Gravis Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Myasthenia Gravis Drugs Average Price (USD/Kg) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Myasthenia Gravis Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Myasthenia Gravis Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Myasthenia Gravis Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Myasthenia Gravis Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Myasthenia Gravis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myasthenia Gravis Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Myasthenia Gravis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Myasthenia Gravis Drugs Sales by Region (2020-2025) & (MT)
 Table 18. Global Myasthenia Gravis Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Myasthenia Gravis Drugs Sales by Region (2026-2031) & (MT)
 Table 20. Global Myasthenia Gravis Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Myasthenia Gravis Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Myasthenia Gravis Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Myasthenia Gravis Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Myasthenia Gravis Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Myasthenia Gravis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Myasthenia Gravis Drugs Sales by Country (2020-2025) & (MT)
 Table 27. North America Myasthenia Gravis Drugs Sales by Country (2026-2031) & (MT)
 Table 28. North America Myasthenia Gravis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Myasthenia Gravis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Myasthenia Gravis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Myasthenia Gravis Drugs Sales by Country (2020-2025) & (MT)
 Table 32. Europe Myasthenia Gravis Drugs Sales by Country (2026-2031) & (MT)
 Table 33. Europe Myasthenia Gravis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Myasthenia Gravis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Myasthenia Gravis Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Myasthenia Gravis Drugs Sales by Region (2020-2025) & (MT)
 Table 37. Asia Pacific Myasthenia Gravis Drugs Sales by Region (2026-2031) & (MT)
 Table 38. Asia Pacific Myasthenia Gravis Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Myasthenia Gravis Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Myasthenia Gravis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Myasthenia Gravis Drugs Sales by Country (2020-2025) & (MT)
 Table 42. Latin America Myasthenia Gravis Drugs Sales by Country (2026-2031) & (MT)
 Table 43. Latin America Myasthenia Gravis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Myasthenia Gravis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Myasthenia Gravis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2020-2025) & (MT)
 Table 47. Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2026-2031) & (MT)
 Table 48. Middle East and Africa Myasthenia Gravis Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Myasthenia Gravis Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Myasthenia Gravis Drugs Sales (MT) by Type (2020-2025)
 Table 51. Global Myasthenia Gravis Drugs Sales (MT) by Type (2026-2031)
 Table 52. Global Myasthenia Gravis Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Myasthenia Gravis Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Myasthenia Gravis Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Myasthenia Gravis Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Myasthenia Gravis Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Myasthenia Gravis Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Myasthenia Gravis Drugs Price (USD/Kg) by Type (2020-2025)
 Table 59. Global Myasthenia Gravis Drugs Price (USD/Kg) by Type (2026-2031)
 Table 60. Global Myasthenia Gravis Drugs Sales (MT) by Application (2020-2025)
 Table 61. Global Myasthenia Gravis Drugs Sales (MT) by Application (2026-2031)
 Table 62. Global Myasthenia Gravis Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Myasthenia Gravis Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Myasthenia Gravis Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Myasthenia Gravis Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Myasthenia Gravis Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Myasthenia Gravis Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Myasthenia Gravis Drugs Price (USD/Kg) by Application (2020-2025)
 Table 69. Global Myasthenia Gravis Drugs Price (USD/Kg) by Application (2026-2031)
 Table 70. Flamel Technologies Company Information
 Table 71. Flamel Technologies Description and Business Overview
 Table 72. Flamel Technologies Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 73. Flamel Technologies Myasthenia Gravis Drugs Product
 Table 74. Flamel Technologies Recent Developments/Updates
 Table 75. F. Hoffmann-La Roche Company Information
 Table 76. F. Hoffmann-La Roche Description and Business Overview
 Table 77. F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 78. F. Hoffmann-La Roche Myasthenia Gravis Drugs Product
 Table 79. F. Hoffmann-La Roche Recent Developments/Updates
 Table 80. Grifols Company Information
 Table 81. Grifols Description and Business Overview
 Table 82. Grifols Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 83. Grifols Myasthenia Gravis Drugs Product
 Table 84. Grifols Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 88. Pfizer Myasthenia Gravis Drugs Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Takeda Company Information
 Table 91. Takeda Description and Business Overview
 Table 92. Takeda Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 93. Takeda Myasthenia Gravis Drugs Product
 Table 94. Takeda Recent Developments/Updates
 Table 95. Novartis Company Information
 Table 96. Novartis Description and Business Overview
 Table 97. Novartis Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 98. Novartis Myasthenia Gravis Drugs Product
 Table 99. Novartis Recent Developments/Updates
 Table 100. Bausch Health Company Information
 Table 101. Bausch Health Description and Business Overview
 Table 102. Bausch Health Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 103. Bausch Health Myasthenia Gravis Drugs Product
 Table 104. Bausch Health Recent Developments/Updates
 Table 105. Alexion Pharmaceuticals Company Information
 Table 106. Alexion Pharmaceuticals Description and Business Overview
 Table 107. Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 108. Alexion Pharmaceuticals Myasthenia Gravis Drugs Product
 Table 109. Alexion Pharmaceuticals Recent Developments/Updates
 Table 110. Catalyst Pharmaceuticals Company Information
 Table 111. Catalyst Pharmaceuticals Description and Business Overview
 Table 112. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 113. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product
 Table 114. Catalyst Pharmaceuticals Recent Developments/Updates
 Table 115. CSL Company Information
 Table 116. CSL Description and Business Overview
 Table 117. CSL Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 118. CSL Myasthenia Gravis Drugs Product
 Table 119. CSL Recent Developments/Updates
 Table 120. Curavac Company Information
 Table 121. Curavac Description and Business Overview
 Table 122. Curavac Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 123. Curavac Myasthenia Gravis Drugs Product
 Table 124. Curavac Recent Developments/Updates
 Table 125. Cytokinetics Company Information
 Table 126. Cytokinetics Description and Business Overview
 Table 127. Cytokinetics Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 128. Cytokinetics Myasthenia Gravis Drugs Product
 Table 129. Cytokinetics Recent Developments/Updates
 Table 130. Galencia Company Information
 Table 131. Galencia Description and Business Overview
 Table 132. Galencia Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 133. Galencia Myasthenia Gravis Drugs Product
 Table 134. Galencia Recent Developments/Updates
 Table 135. GlaxoSmithKline Company Information
 Table 136. GlaxoSmithKline Description and Business Overview
 Table 137. GlaxoSmithKline Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 138. GlaxoSmithKline Myasthenia Gravis Drugs Product
 Table 139. GlaxoSmithKline Recent Developments/Updates
 Table 140. Lupin Pharmaceuticals Company Information
 Table 141. Lupin Pharmaceuticals Description and Business Overview
 Table 142. Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 143. Lupin Pharmaceuticals Myasthenia Gravis Drugs Product
 Table 144. Lupin Pharmaceuticals Recent Developments/Updates
 Table 145. Mitsubishi Tanabe Pharma Company Information
 Table 146. Mitsubishi Tanabe Pharma Description and Business Overview
 Table 147. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 148. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product
 Table 149. Mitsubishi Tanabe Pharma Recent Developments/Updates
 Table 150. Key Raw Materials Lists
 Table 151. Raw Materials Key Suppliers Lists
 Table 152. Myasthenia Gravis Drugs Distributors List
 Table 153. Myasthenia Gravis Drugs Customers List
 Table 154. Myasthenia Gravis Drugs Market Trends
 Table 155. Myasthenia Gravis Drugs Market Drivers
 Table 156. Myasthenia Gravis Drugs Market Challenges
 Table 157. Myasthenia Gravis Drugs Market Restraints
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Myasthenia Gravis Drugs
 Figure 2. Global Myasthenia Gravis Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Myasthenia Gravis Drugs Market Share by Type: 2024 & 2031
 Figure 4. Anticholinesterases Product Picture
 Figure 5. Immunosuppressants Product Picture
 Figure 6. Intravenous Immune Globulins Product Picture
 Figure 7. Global Myasthenia Gravis Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Myasthenia Gravis Drugs Market Share by Application: 2024 & 2031
 Figure 9. Hospitals
 Figure 10. Clinics
 Figure 11. Global Myasthenia Gravis Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Myasthenia Gravis Drugs Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Myasthenia Gravis Drugs Sales (2020-2031) & (MT)
 Figure 14. Global Myasthenia Gravis Drugs Average Price (USD/Kg) & (2020-2031)
 Figure 15. Myasthenia Gravis Drugs Report Years Considered
 Figure 16. Myasthenia Gravis Drugs Sales Share by Manufacturers in 2024
 Figure 17. Global Myasthenia Gravis Drugs Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Myasthenia Gravis Drugs Players: Market Share by Revenue in Myasthenia Gravis Drugs in 2024
 Figure 19. Myasthenia Gravis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Myasthenia Gravis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Myasthenia Gravis Drugs Sales Market Share by Country (2020-2031)
 Figure 22. North America Myasthenia Gravis Drugs Revenue Market Share by Country (2020-2031)
 Figure 23. U.S. Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Myasthenia Gravis Drugs Sales Market Share by Country (2020-2031)
 Figure 26. Europe Myasthenia Gravis Drugs Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Region (2020-2031)
 Figure 34. China Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Taiwan Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Philippines Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Latin America Myasthenia Gravis Drugs Sales Market Share by Country (2020-2031)
 Figure 45. Latin America Myasthenia Gravis Drugs Revenue Market Share by Country (2020-2031)
 Figure 46. Mexico Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Brazil Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Argentina Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. U.A.E Myasthenia Gravis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Myasthenia Gravis Drugs by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Myasthenia Gravis Drugs by Type (2020-2031)
 Figure 56. Global Myasthenia Gravis Drugs Price (USD/Kg) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Myasthenia Gravis Drugs by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Myasthenia Gravis Drugs by Application (2020-2031)
 Figure 59. Global Myasthenia Gravis Drugs Price (USD/Kg) by Application (2020-2031)
 Figure 60. Myasthenia Gravis Drugs Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Myasthenia Gravis MG Treatment Market Research Report 2024
Global Autoimmune Diseases Treatment Market Research Report 2024
Global Medicines for Alzheimer Disease Treatment Market Research Report 2025
Global Still s Disease Treatment Market Research Report 2025
Global Cardiovascular Disease Nursing Drugs Market Research Report 2025
Global Treatment Planning Software Market Research Report 2025
Global Combination Therapy Drug Market Research Report 2025
Global Weekly Pill Organizer Market Research Report 2025
Global Drug Safety and Pharmacovigilance Service Market Research Report 2025
Global Pharmaceutical Validation Services Market Research Report 2025
Global Pill Organizer with Timer Reminder Market Research Report 2025
Global Pharmerging Market Research Report 2025
Global Ophthalmology AI assisted Diagnosis Software Market Research Report 2024
Global Ant Killer Market Research Report 2024
Global CGT Drugs Market Research Report 2025
Global Rabies Treatment Market Research Report 2024
Global Coding and Marking for Pharmaceuticals and Consumer Products Market Research Report 2024
Global Immune Drugs Market Insights Forecast to 2030
Global Reproductive and Fertility Diagnosis Market Research Report 2025
Global Gynecological Cancers Drug Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions